Knowledge and practices of general practitioners of district Peshawar about schizophrenia by Irfan, Muhammad
NEW UNIVERSITY OF LISBON 







“KNOWLEDGE AND PRACTICES OF GENERAL PRACTITIONERS OF 
DISTRICT PESHAWAR ABOUT SCHIZOPHRENIA” 
 
 
DR. MUHAMMAD IRFAN 
















Schizophrenia with its disabling features has been placed in the top 
ten of global burden of disease and is associated with long-term 
decline in functional ability. General Practitioners not only have an 
important role in treating patients with an established diagnosis of 
schizophrenia but they can also contribute significantly by identifying 
people in early stages of psychosis as they are the first hand medical 
help available and the duration of untreated psychosis is a good 
indicator of patient’s prognosis. 
This cross sectional survey, conducted at the clinics of General 
Practitioners, was designed to assess the knowledge and practices 
of general practitioners in Peshawar on diagnosis and treatment of 
schizophrenia. A semi structured questionnaire was used to assess 
their knowledge and practices regarding schizophrenia. The 
Knowledge/Practice was then categorized as good or poor based on 
their responses to the questions of the administered questionnaire. 
Overall, the results showed that the knowledge and practices of 
general practitioners of district Peshawar were poor regarding 
schizophrenia and may be responsible for delayed diagnosis, 
inadequate treatment and poor prognosis. 
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Schizophrenia is a disorder which involves chronic or recurrent 
psychosis and can lead to long-term decline in functional ability1. It is 
placed in the top ten causes of disability in the Global Burden of 
Disease because it has an early adulthood onset, lifelong course, 
lack of social acceptability and incapacitating symptoms, which 
collectively make it one of the most disabling and financially 
catastrophic disorders2. In 1990, the estimated loss in DALY’s due to 
schizophrenia and associated disorders was around 13 million 
representing almost 1% of burden of the disease from all causes and 
was ranked 26th in the list2. By the year 2020, Schizophrenia is 
projected to be in 20th position with a DALY’s loss of more than 17 
million and 1.25% of the overall burden2. It is estimated to have a 
lifetime risk of 0.2 to 0.7%3, with 11/ 100,000 as an annual 
incidence4. The course of illness for an individual patient is difficult to 
predict. About 10 % of patients recover from an initial episode and do 
not experience any further impairment but the majority i.e., 55 % has 
chronic symptoms and the remainders experience an intermittent 
course5. Relapse of psychosis is highly associated with 
discontinuation (& non compliance) of antipsychotic medication, as 
well as with substance abuse, psychosocial stressors, and physical 
illness 6-11.  
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Schizophrenia affects about 24 million people worldwide with more 
than 50% of these, not receiving appropriate care and out of 90 % of 
these, residing in developing countries, Pakistan being one of 
them12. Variation in the prevalence of schizophrenia across 
geographic regions, populations and ethnic groups has been 
suggested but not confirmed13. The exact prevalence of 
schizophrenia in Pakistan is not known which prevents the making of 
national level strategies to combat this incapacitating and 
burdensome illness. Taking in account the global prevalence and the 
draft of “Assessment of Health Status & Trends in Pakistan”, the 
estimated prevalence of schizophrenia in Pakistan may be 1-2% in 
the general population14 although it varies among rural and urban 
population of various provinces. In Punjab, it is 2.5% for urban while 
that in rural is 2%. In Sindh, it is 2% for urban while 1.5% for rural 
population. In Khyber Pakhtunkhwa, it is estimated to be 2% in urban 
and 2.5% for rural population. Baluchistan has the lowest with 1% 
each in urban and rural population15. 
This is a well known fact that Schizophrenia is best treated in 
specialty clinics but there is a very low number of Psychiatrists and 
specialty clinics and centers for the diagnosis and treatment of 
schizophrenia in Pakistan15. General Practitioners, therefore, have 
an important role in treating the cases with an established diagnosis 
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of schizophrenia16 as well as in identifying people in the early stages 
of psychosis17 as they are mostly the first hand medical help 
available. They come across the diagnosis in a variety of contexts 
including initial presentation, provision of support to family members, 
evaluation of concurrent medical illness, management of medication 
side effects and primary treatment when specialty options are not 
available and offer an effortless and non-stigmatizing access to 
health care, to the people18. Interestingly, there are only a few 
studies that focus on the knowledge and practice of General 
practitioners in dealing with patients of schizophrenia around the 
globe19-22. Therefore, it was decided to conduct a study to assess the 
knowledge and practices of General Practitioners of district 
Peshawar about Schizophrenia to highlight the magnitude of the 
issue and to address the gaps in knowledge and practice in this 
context and to make plans for improvement, if required. 
In Chapter 1, we will review the existing literature on schizophrenia, 
the role of general practitioners and the situation of general practice 
in Pakistan. In Chapter 2, we will present the details of the Original 
study conducted while Chapter 3 focuses on the tables and figures of 
the Original study. Chapter 4 and 5 describe the references and the 
proforma used to assess the knowledge and practices of General 
Practitioners of district Peshawar about Schizophrenia. 
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CHAPTER 1: LITERATURE REVIEW 
1.1 GENERAL PRACTICE IN PAKISTAN 
General practitioners (GPs) constitute the majority of health care 
providers in most parts of the world, treating major bulk of patients 
and serving as the back bone of any health care system23. They 
make up about 85% of all the registered doctors and are responsible 
for managing approximately 80% of patients in Pakistan23. However, 
studies conducted in Pakistan show lack of knowledge and essential 
expertise in practice of general practitioners' regarding basic health 
issues23-25. The situation is even worse in rural areas of Pakistan, 
comprising of 66% population of the country, as specialists and 
better health facilities are often concentrated in cities creating an 
imbalance in health service provision26. So, comparatively, there is a 
poor quality of care in rural areas and therefore higher chance of 
misdiagnoses or inappropriate referral.  
There can be many reasons including the fact that most of the 
general practitioners do not possess any additional qualification after 
graduating from medical school and are not re assessed thereafter 
for their competency27. This creates professional isolation by virtue of 
staying away from the teaching atmosphere, having none or few 
opportunities to improve their existing knowledge27.  
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General practice in Pakistan is comparatively a new and an 
underdeveloped specialty of medicine with formal training program 
by the name of Family Medicine initiated by College of Physicians 
and Surgeons Pakistan (CPSP) in 199228. Soon after, this training 
program got discontinued and has restarted just a few years back28. 
Till date, a very few number of institutions are recognized for the 
training and the total number of fellows of CPSP in the subject of 
Family Medicine are just 4329. So all the other general practitioners in 
Pakistan, unless qualified from abroad with degrees like Members of 
Royal College of General Practitioners, are just medical school 
graduates. They need regular program of continuous medical 
education formulated by Pakistan Medical and Dental Council, the 
national health regulatory authority, followed by establishing a 
competency assurance system to ensure the best possible health 
care delivery to the public30.  
Like other developing countries, the number of Psychiatrists for the 
diagnosis and treatment of schizophrenia is very low15. Thus, 
Pakistan is a good case to advocate the importance of the role of 
general practitioners in this regard16, 17 as they can help in treating 
the psychiatric disorders, which are reported as the third most 
common reason for consultation in primary care, in an unstigmatized 
manner31, 32.  
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1.2 INTRODUCTION TO SCHIZOPHRENIA 
Schizophrenia, apart from being in the top ten list of the Global 
Burden of Disease 2, 33, is also ranked 6th as a cause of disability 
worldwide, measured by Years of Life lived with Disability34. The 
word schizophrenia, roughly translated as “splitting of the mind” is 
derived from the Greek roots schizein “to split”, and phren “mind” 35, 
36. A detailed case report by John Haslam and accounts by Phillipe 
Pinel in 1809, are often considered as the earliest reported cases37, 
38. 
Schizophrenia is estimated to reduce the life expectancy by 
approximately 10 years. Schizophrenia, according to the Global 
Burden of Disease Study, causes a high degree of disability 
accounting for 1.1% of the total disability-adjusted life years (DALYs) 
and 2.8% of years lived with disability (YLDs). In the age group 15–
44 years, it is the 8th leading cause of DALYs worldwide, according 
to the World Health Report 39.  
Although significant advancement has been attained in the diagnosis, 
treatment and the disorder’s neurobiological substrates, a 
comprehensive knowledge of its origins and pathogenic mechanisms 





1.3 EPIDEMIOLOGY OF SCHIZOPHRENIA 
Psychotic disorders (divided over 12 different diagnostic categories) 
have a total lifetime prevalence of 3.5%41. For Schizophrenia, the 
incidence is relatively low (11 to 15.2 per 100,000) 4, 42 with wide 
variation of rise and fall in different populations including those with 
co morbidities 43, 44 but the prevalence remains substantially variable 
across populations, ethnic groups and geographic regions with the 
consideration of using a different type of prevalence estimate45, 46, 
tendency to start early in adult life and become chronic47. The range 
of 1-2.5% has also been reported in various areas of Pakistan 15. 
At an average, it is accepted that schizophrenia affects 1% of the 
population, with similar rates across different countries, cultural 
groups, and sexes 48. 
Schizophrenia typically presents in early adulthood and has a 
tendency to develop between 16 and 30 years of age, mostly 
persisting throughout the patient’s lifetime48. An increase in onset 
after puberty, which continues throughout adolescence and peaks in 
the twenties, is reported which then start decreasing from the thirties 
and tends to tail off in the fifties49. 
Childhood-onset schizophrenia is defined by an onset of psychotic 
symptoms before 13 years of age50. The illness occurs at a younger 
age in those with positive family history of schizophrenia51. Since the 
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practice of psychiatry in Pakistan is mostly “General Adult” based, a 
patient of schizophrenia with a childhood or adolescent onset may be 
too late to present, in terms of prognosis. General Practitioner may 
have a very important role in diagnosing these cases early when 
such patients are brought to them with psychotic symptoms 
attributed to various cultural issues. 
With a gender ratio of 1.4:1 male: female, Schizophrenia is more 
common in men than women44, 52. Studies show that the age of onset 
of disease is earlier in males than in females by 3 to 5 years, 
regardless of culture53. Typically, men exhibit symptoms at an earlier 
age with a worse prognosis. The peak age of onset is in the early 
twenties, with very few cases occurring after 45 years of age54.  
The presence of Schizophrenia in African and Caribbean people 
residing in the United Kingdom, compared to the native white 
population was reported to be 6 times drawing attention to cultural 
considerations55. The rates are higher in the children of migrants56. 
This may suggest that either the perceived discrimination of the 
ethnic minority groups or some factor closely related to it is 
contributing to their increased risk of schizophrenia57.  
In the “Ethnic Minority Psychiatric Illness Rates in the Community” 
(EMPIRIC) study, the prevalence of psychosis, among participants of 
Caribbean, Irish, Bangladeshi, Pakistani and Indian ethnicities, was 
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three times higher in those experiencing verbal racism, and five times 
higher in those having a racist physical attack, than in those who did 
not, supporting the above mentioned social hypothesis58.  
There is a two way relationship between Schizophrenia and 
unemployment/ singleness as these increases the risk of developing 
schizophrenia and subsequently schizophrenia increases the risk of 
unemployment and singleness59. Even in the developed countries, 
although employment rates may be higher for them but they still are 
unable to fully support themselves60. In Pakistan, psychiatric 
disorders are more common in population with low socioeconomic 
status in rural areas and dominantly involve the males 61. 
Area of residence also has an important effect on the rates of 
schizophrenia. Residing in areas of increasing population density 
increases the hospitalization risk in men with vulnerability for 
schizophrenia which is expressed as poor cognitive and social 
abilities 62, 63.  
There is evidence that schizophrenia is more common in those born 
in cities, and that the larger the city and the longer a person has lived 
there, the greater the risk42. Schizophrenia is also thought to be 
related to lower social class64. Material deprivation is also likely to 
influence admission rates for psychosis but social fragmentation has 
the greatest effect65.   
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1.4 SYMPTOMS OF SCHIZOPHRENIA 
In general population, 4.4% report incident psychotic symptoms66. 
There is mostly a prodromal period before the onset of psychosis 
which is characterized by various mental disturbances like negative 
symptoms, attenuated and brief transient frank psychotic symptoms, 
cognitive impairments, and a marked decline is observed in social 
functioning and quality of life67.  
Eugen Bleuler described the main symptoms of schizophrenia in 
1908 as 4 A's: flattened Affect, Autism, impaired Association of ideas 
and Ambivalence68. Kurt Schneider, a German psychiatrist 
considered certain symptoms as characteristic of schizophrenia and 
thus called these as “first rank symptoms”69, 70. 
The characteristic symptoms of schizophrenia fall into broad 
categories of positive and negative symptoms with other associated 
symptoms of cognitive impairment and affective disturbance 33. 
1.4.1 POSITIVE SYMPTOMS 
These are synonymous with psychosis. "Positive" refers to the active 
quality of these symptoms, whose presence is abnormal. Positive 
symptoms are correlated with first-time diagnosis and hospital 
admission, but have little predictive value for long-term course. 
Delusions are the most common symptom, occurring in 65 percent of 
patients71, 72. Hallucinations and thought disorganization each are 
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described in about 50 percent of patients 73, 74. A large number of 
patients experience a combination of delusions, hallucinations, and 
disorganization71. Positive symptoms are the most responsive to 
pharmacological treatment, though they may wax and wane 75. 
1.4.2 NEGATIVE SYMPTOMS 
Negative symptoms represent the diminution or absence of normal 
characteristics and include flat/ blunted affect and emotion, alogia 
(poverty of speech), anhedonia (inability to experience pleasure), 
asociality (lack of desire to form relationships), and avolition (lack of 
motivation) 33, 76. These deficits may occur months or years before 
the onset or detection of psychotic symptoms 77 and are moderately 
correlated with functional incapacity, particularly at work78, 79. 
Evidence suggests that patients suffering from schizophrenia often 
exhibit a normal or even increased level of emotionality, especially in 
response to negative events80. Contradictory evidence shows that 
patients with schizophrenia experience both receptive and 
expressive deficits81, 82. That is, they not only appear blank to others, 
but see the people around them in the same way. 
1.4.3 OTHER SYMPTOMS 
Schizophrenia is associated with a wide range of deficits in 
neurocognitive function including attention, memory, language and 
executive function83, 84. Significant deficits are present by birth, 
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followed by moderate decline additionally with the onset of active 
illness, in most cases85-87. School performance and cognitive testing 
of individuals who later developed schizophrenia, when reviewed 
retrospectively, showed a pattern of poor performance 88, 89. 
Cognitive problems are highly correlated with functional impairment 
of the patient90.  
The combination of inappropriate, odd and blunted expression is the 
most frequently observed affective disturbance and is stigmatizing in 
social settings 91. In early schizophrenia, depressive mood is 
reported in upto 81% of individuals with first-episode while 
depression is reported in about 22% of those with first-episode 92, 93. 
Suicide is also reported commonly either at the beginning of 
treatment or after the resolution of an acute episode or while shifting 
from hospital to outpatient care94. Overall, mood disturbance occurs 
at about four times the rate seen in the general population95. 
Few other symptoms worth mentioning include disorganization 
syndrome (chaotic speech, thought, and behavior)96, catatonia (an 
altered state of motor activity and attention), echopraxia 
(inappropriately mirroring movements), echolalia (repeating speech 
in a rigid and stereotypic way), stereotypic and bizarre movements, 
stuporous appearance or may be internally preoccupation with other 
psychotic symptoms33.  
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1.5 DIAGNOSIS OF SCHIZOPHRENIA 
The presentation of schizophrenia varies significantly with a wide 
range of psychotic manifestations and varying levels of functional 
incapacity. Schizophrenia is a challenging diagnosis because there 
are neither pathognomonic features nor confirmatory laboratory or 
neuropsychological tests.  
The most widely used diagnostic criteria for schizophrenia were 
developed by WHO (International Classification of Diseases, ICD-10) 
and American Psychiatric Association (Diagnostic and Statistical 
Manual of Mental Disorders, DSM-IV-TR) with little differences. The 
ICD-10 criteria emphasize more on Schneiderian First Rank 
Symptoms suggested by Kurt Schneider97, 98. The ICD 10 includes 
Paranoid Schizophrenia; Hebephrenic Schizophrenia; Catatonic 
Schizophrenia; Undifferentiated Schizophrenia; Residual 
Schizophrenia; Post Schizophrenic Depression; Simple 









1.6 AETIOLOGY OF SCHIZOPHRENIA 
The main risk factors are genetic causes, pregnancy and delivery 
complications, slow neuromotor development, and deviant cognitive 
and academic performance107. 
1.6.1 NEURODEVELOPMENTAL AND GENETIC CAUSES 
Recent studies suggest that abnormalities can be observed years 
before the onset of positive symptoms108.  
The concordance rate for schizophrenia between monozygotic twins 
is 50 percent109. Studies have identified possible gene associations 
e.g., neuregulin-1 gene, presence of a susceptibility gene (ZNF804A) 
and increase in gene structural variants110-114. It is now widely 
suspected that there is no single genetic determinant and multiple 
genetic factors work in combination to create the vulnerability115.  
Advanced paternal age is more prevalent in schizophrenia patients 
and insults to fetal development occurring in first and second 
trimester and exposure to psychoactive substances, especially 
cannabis are correlated with an increased risk116-122. 
1.6.2 ENVIRONMENT AND SOCIAL CAUSES 
Urbanization, social and racial adversity, family dysfunction and 
unemployment have all been proposed as risk factors 48, 63, 123.  
It is suggested that winter or spring birth and prenatal exposure to 
infections is associated with developing schizophrenia later 124,125.  
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Childhood experiences of abuse or trauma and unsupportive 
dysfunctional parental relationships have also been noted as risk 
factors for a diagnosis of schizophrenia126, 127. 
There is a two way relationship is proposed to exist between 
schizophrenia and drugs of abuse or alcohol128. 
1.6.3 DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA 
It has been suggested that positive symptoms are due to 
hyperactivity of dopaminergic projections from the midbrain while 
negative and cognitive symptoms are correlated with a decrease in 
prefrontal activity of dopaminergic pathways 129, 130.  
1.6.4 STRUCTURAL BRAIN CHANGES 
Schizophrenic brains are smaller than normal brains, with ventricular 
enlargement and thinning of neuritic processes without loss of 
neuronal bodies131-133. Medial temporal lobes are found to be smaller 










1.7 COURSE OF SCHIZOPHRENIA 
Schizophrenia has a quite consistent natural history and 
longitudinal course. Many patients treated in their first episode of 
schizophrenia show a good response to treatment and achieve 
some symptom remission and level of recovery, but recurrent 
episodes lead to significant neurological deterioration136. The role 
of General practitioner is vital in the early diagnosis of such cases 
where they sometimes receive the patients with other co 
morbidities. 
Few patients once diagnosed of having schizophrenia, enjoy 
complete remission. Living in a house hold of 3 or more adults, 
later age of onset and taking antipsychotics predict complete 
remission137. 
The overall rate of recovery during the early years of the illness is 
low but some patients with first-episode schizophrenia can achieve 
sustained symptomatic and functional recovery138. Patients in 
remission require markedly less health care resources139. 
It is also a well known fact that premorbid functioning is associated 
with better response to treatment, fewer extra pyramidal symptoms 
and better recovery140. The duration of untreated psychosis also 
significantly affects the course of the illness, its symptom severity 
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and outcome of the illness. The longer the duration of untreated 
psychosis, the poor is the prognosis141.  
In a nutshell, Schizophrenia is associated with a 20 percent 
reduction in life expectancy and worse physical health than in the 
general population142, 143. 
1.7.1 MORTALITY 
Patients with schizophrenia have a higher mortality and nearly a 
quarter of deaths resulting from unnatural causes144. Suicide rates 
in schizophrenia and other psychotic disorders appear to be 20-fold 
higher145. At the same time deliberate self harm or suicide attempt 
is also thought to be a predictor of relapse146.  
1.7.2 COMORBIDITY 
The most common comorbid condition is substance abuse. As 
many as 80 percent of patients of schizophrenia abuse alcohol, 
illicit drugs, or prescription medications147-149. 
Patients of schizophrenia with comorbid cannabis abuse have more 
positive symptoms and show more violent behaviour150.  
Increased rates of chronic medical conditions like coronary artery 
disease, chronic obstructive pulmonary conditions, hepatitis, 
hypothyroidism, diabetes mellitus, fluid and electrolyte disorders 




1.8 MANAGEMENT OF SCHIZOPHRENIA 
The introduction of chlorpromazine in the 1950s, changed the 
complete scenario of management of schizophrenia as previously, 
the care of patients suffering from schizophrenia was limited to 
various rehabilitative, psychotherapeutic and custodial 
interventions. The advent of relatively safe and effective 
pharmacologic treatments paved the path for marked improvement 
in symptoms and functioning and made it possible for the majority 
of the patients to live in community settings152. Effective treatment 
interventions using a combination of best possible 
pharmacotherapy and targeted psychosocial treatments are 
elevating expectations about the prospects of functional recovery in 
patients with schizophrenia153.  
1.8.1 PSYCHOSOCIAL INTERVENTIONS 
There are various guidelines for the treatment of schizophrenia 
developed across the world. These recommend nearly similar 
pharmacotherapy but have variations in the type of psychosocial 
interventions which describes their importance154, 155. 
Psychological interventions for schizophrenia include cognitive 
behavioral therapy for symptoms, cognitive remediation for 
neurocognitive deficits, motivational interventions for substance 
misuse and for non-adherence to medication and family 
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interventions 156. Social skills’ training is planned to deal with the 
deficits in patient's communication and social interactions157. A 
recent study, reported in Pakistan showed promising preliminary 
results with the use of CBT in patients with psychosis158.  
Vocational rehabilitation is useful at getting patients into the place 
of work, although they may rarely work in a long-term competitive 
employment159. 
1.8.2 PHARMACOLOGICAL TREATMENT 
There are three basic classes of medications (typical, atypical and 
dopamine partial agonist antipsychotics) which act principally on 
dopamine systems160. The typical antipsychotic agents have been 
associated with relatively high incidence of adverse effects ranging 
from acute dystonia to akathesia and akinesia to tardive dyskinesia 
and neuroleptic malignant syndrome161. Atypical agents with greater 
affinities for serotonin and norepinephrine162 lead the patients to 
receive significantly less prescriptions for anticholinergics163. 
Clozapine, dopamine partial agonist, remains the treatment of choice 
for refractory schizophrenia, although it is well known to cause blood 
dyscrasias and other serious adverse effects such as seizures, 




Obesity, type 2 diabetes mellitus, and hyperlipidemia (the metabolic 
syndrome) occur both with schizophrenia and with antipsychotic 
medications165-168. Cardiac risk associated with schizophrenia and 
with antipsychotic drugs has recently been fully appreciated169-171. 
Antipsychotic medications vary in their propensity to cause QTC 
prolongation but a particular concern is with intravenous use of 
haloperidol, which has led to fatality and a 2007 FDA alert172. 
In Pakistan, drug non-compliance has been a major hindrance in the 
effective management of schizophrenia. Nearly 74% of the patients 
have a relapse of the illness and need frequent readmissions 
resulting from the non-compliance 173. Non-affordability of drugs, 
unawareness of the benefits of treatment, physical side effects and 












1.9 GENERAL PRACTITIONERS AND SCHIZOPHRENIA 
In Low and Middle Income countries, most people with schizophrenia 
probably receive little or no formal care. One manifestation of this is 
very long duration of untreated psychosis in the first episode, i.e., 
132 weeks174. This poses a major public health problem considering 
that around 41.7 million people with schizophrenia may need care in 
these countries175. The general practitioners, therefore, have to play 
a crucial role in early diagnosis and management, as they come 
across these cases in various contexts. To fulfill the role, the general 
practitioners need diagnostic knowledge, low-threshold, easily 
accessible specialized services to which they can refer these 
patients. 
The movement, and then the subsequent policies in favour of closing 
the mental hospitals and transferring these to community services 
have been campaigned for quite some time176 and are being actively 
pursued recently177. This may also increase the role of general 
practitioners being the physicians readily available in the community.  
Guidelines for schizophrenia management in general practice 
emphasize on the early diagnosis of psychosis, minimizing delays in 
treatment initiation, keeping an eye on the patient’s condition and 
treatment adherence, and prompt intervention at times of relapse or 
psychosocial crises178-184. The early diagnosis of psychosis, thus, 
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becomes very important as it is the central part of ‘‘mental health 
literacy’’ which is mandatory for appropriate help-seeking185, and the 
general practitioners can play a pivotal role in this regard. 
General practitioners may be less confident in the clinical skills than 
a psychiatrist regarding schizophrenia but can see themselves 
complementing the psychiatrist with an active and useful role186. The 
level of confidence can be improved by including mental health in the 
undergraduate curriculum and by providing pre service training to the 
general practitioners. Once they feel confident about the knowledge, 
the universal screening should be emphasized to improve detection 
rates of mental disorders including schizophrenia for which brief 
mental health screening questionnaires might help187. 
Unfortunately, there are only a few studies that focus on the 
knowledge and practice of General practitioners about 
schizophrenia, around the globe19-22. The authors are not aware of 
studies from other developing countries which address this issue 
except a study in a semi urban small border district in Pakistan with a 
smaller sample size using the same proforma22. It was therefore 
decided to conduct a study to assess the knowledge and practices of 
General Practitioners about schizophrenia in a major urban center, 
Peshawar, to identify the gaps in knowledge and practice in service 
delivery, and chalk out plans to improve it, if needed. 
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To assess the knowledge and practices of general practitioners in 
district Peshawar on diagnosis and treatment of schizophrenia. 
To estimate the frequency of patients of schizophrenia, seen in 


















2.2 SUBJECTS AND METHODS 
2.2.1 Sample 
This cross sectional survey was conducted at the clinics of General 
Practitioners in Peshawar from August 2009 to December 2011. A 
list of General Practitioners of Peshawar, enrolled with provincial 
Health Regulation Authority was obtained and all the 135 listed 
General Practitioners were contacted for the purpose of the survey. 
Unlike the countries such as UK, in Pakistan the GPs are not defined 
by their registration or after a specified period of training. For the 
purpose of this study a General Practitioner was defined as, "A 
licensed medical graduate registered with Health Regulatory 
Authority who gives personal, primary and continuing care to 
individuals, families and a practice population irrespective of age, sex 
and illness"188.  
All the enlisted (n=135) were approached to give consent to 
participate in the study. Out of 135, 114 consented to participate in 
the study and were included through purposive, non-probability 
sampling. The study was given ethical approval by the institutional 
review and ethical board, Postgraduate Medical Institute, Lady 
Reading Hospital Peshawar.  
Twenty One General Practitioners did not consent to participate in 
the study.  
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It is worth mentioning that most of the general practices in Peshawar 
are single doctor based practices providing service for fee. The GPs 
only provide curative services and patients meet the treatment costs 
through out of pocket expenses. 
2.2.2 Questionnaire 
The participating General Practitioners were then requested to 
answer a semi structured questionnaire (Appendix A) consisting of 
three parts namely, General Information, Knowledge and Practices 
related to Schizophrenia. This questionnaire has been used by 
Simon AE et al in their seminal study and has been validated for use 
with GPs19. As this questionnaire was developed in Switzerland 
where the health system and the practice of GP differs markedly 
from that in Pakistan, the questionnaire was modified to reflect the 
practice and health services in Pakistan. However, we retained the 
major domains, questions and content as developed by Simon AE et 
al19. The 17 item questionnaire consisted of 5 demographic items 
and 12 (partly multi-item) questions that assessed: Knowledge 
(symptoms of schizophrenia; early warning signs of schizophrenia; 
treatment; and management of schizophrenia patients) and Practice 
(methods used to confirm diagnosis; referrals used; and medications 
prescribed to schizophrenia patients) and continuing medical 
education of the Practitioner. 
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Knowledge was defined as the ability of the general practitioner to 
correctly identify the symptoms of schizophrenia and its related 
treatments and appropriate referrals. Similarly practice was defined 
as the ability of the general practitioner to correctly indicate their 
practice in diagnosing, treating and referring schizophrenia patients 
appropriately. The level of knowledge on schizophrenia diagnosis 
and treatment was assessed with two multi-item questions (K1 and 
K3) and five other questions (K2, K4-K7) having a maximum score of 
19. A discriminating index was developed using the composite 
scores obtained by the general practitioners’ responses to all 
knowledge questions. Good knowledge was defined as a composite 
knowledge response score of ≥ 60% and Poor Knowledge was 
defined with a composite knowledge score of < 60%. The practical 
experience of general practitioners with schizophrenia diagnosis, 
treatment and referrals was assessed with four multi-item questions 
(P1 – P4) having a maximum score of 22. A similar discriminating 
index using the composite scores obtained by the general 
practitioners’ responses to all the Practice questions was developed. 
Adequate practice was defined as a composite practice response 
score of ≥ 60% and Inadequate practice was defined with a 
composite practice response score of < 60%.  
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The questionnaires were distributed in the clinics of General 
Practitioners along with a short briefing about the questionnaire. The 
questionnaires were then left at their clinics and a collection time was 
decided with them. The filled questionnaires were collected by re-
visiting their clinics in person. However, not all the GPs provided the 
filled questionnaire on the decided data and there have been 
instances where the collection of the filled questionnaire needed 
many visits.  
The scoring scheme based on the correct answers was developed in 
consultation with the data analyst. All the questions and the items of 
the multi-item questions regarding the knowledge and practice were 
marked as either correct (score=1) or incorrect (score=0). 
2.2.3 Analysis 
Data collected through semi structured questionnaire was analyzed 
using Epi Info Statistical software. The demographic details were 
calculated using percentages, and proportions were calculated using 
the discriminating index of composite scores for Knowledge and 








There were 135 General Practitioners invited to participate in this 
study, in that 114 (84.44%) consented to participate and 21 
(15.56%) declined to participate in the study. Majority of GPs were 
male (n=111, 97%).  
About 13% (n=15) of the General Practitioners in this study treat 
more than 10 schizophrenia patients annually and a majority of 
them see few to none of the schizophrenia patients in Peshawar. 
None of them did possess any specialty training in mental health 
and very few (n=7, 6.1%) General Practitioners received continuing 
medical education regarding schizophrenia (Table 1). 
The 21 General Practitioners who refused to participate gave 
reasons for their non-participation including “I have a busy 
schedule” 13 (61.9%); “I don’t see patients with schizophrenia” 6 
(28.6%); and “I don’t want to fill the questionnaire” 2 (9.5%). 
2.3.1 KNOWLEDGE ABOUT FREQUENT SYMPTOMS OF 
SCHIZOPHRENIA 
The level of Schizophrenia Diagnostic knowledge of Practitioners 
was assessed through multiple questions. A composite score on 
the responses to all the seven knowledge questions (K1-K7) was 
estimated with the response scores ranging from 0 to 16 (Figure 2). 
Good knowledge was identified among 12.2% (n=14) of the 
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surveyed general practitioners with a composite score of >12. 
About 6% (n=7) of the general practitioners had no knowledge at all 
about the diagnosis and treatment of schizophrenia receiving a 
composite knowledge score of 0 and the remaining 81.6% (n=93) of 
general practitioners had very poor knowledge (Table 2). 
The frequent symptoms of schizophrenia were identified correctly 
(>60% correct response) by 31.5% (n=36) of the Practitioners 
surveyed, with a response score of >6. About 60% (n=69) had poor 
knowledge about the frequent symptoms of schizophrenia while 
7.9% (n=9) appeared to have no knowledge about the disease 
(Figure 1). A large number of general practitioners (n=93, 81.6%) 
considered hallucinations and delusions to be the most frequent 
symptoms of Schizophrenia (Table 3).  
Eighty (70.2%) general practitioners considered pharmacotherapy to 
be ideal for a patient with a suspected first schizophrenic episode 
(Table 3). 
Seventy one (62.3%) general practitioners, each, considered that the 
first episode of schizophrenia is preceded by early warning signs and 
estimated the relapse risk of untreated patients during the first year 
after a first schizophrenic episode to be more than 60 percent. Only 
15 (13.2%) considered giving antipsychotic medication for 12-24 
month after a first schizophrenic episode and 16 (14.0%) considered 
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giving it for 3-5 years for maintenance therapy in patients with 
multiple episodes of illness after the remission of an episode.  
Only 6 (5.3%) general practitioners could name two side effects and 
25 (21.9%) reported one side effect while 83 (72.8%) could not 
report any side effect of antipsychotic medication. Extra Pyramidal 
Symptoms were the most relevant side effect reported by 27 
(23.7%) general practitioners followed by weight gain reported by 4 
(3.5%).  
2.3.2 SCHIZOPHRENIA TREATMENT PRACTICES 
A composite score on the responses to all the four practice 
questions (P1-P4) was estimated with the response scores ranging 
from 0 to 18 (Figure 3). Adequate practice was identified among 
28.1% (n=32) of the surveyed general practitioners with a 
composite practice score of >13. About 8.8% (n=10) of the general 
practitioners did not conform at all to the correct practice guidelines 
for diagnosis and treatment of schizophrenia receiving a composite 
practice score of 0 and the remaining 63.1% (n=72) of general 
practitioners had inadequate practice methods employed in their 
clinics with a score of less than 13 (Table 4). 
Regarding the breakdown of the practice questions about 
schizophrenia, a sizable majority of general practitioners (n=87, 
76.3%) relied on personal history and observation over several 
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months for the confirmation of the diagnosis of schizophrenia. On 
the subject of the place of treatment, 68 (59.6%) general 
practitioners were of the opinion of treating patients of 
schizophrenia exclusively in their clinic while 45 (39.5%) considered 
referral to a specialist/psychiatric out-patient department and 
complete handover for treatment. Only 3 (2.6%) general 
practitioners could name four medications with their average doses 
while 66 (57.9%) were not able to name any medication for the 
treatment of schizophrenia. Forty three (37.7%) general 
practitioners correctly reported that prognosis of a treated patient 
after a first episode of schizophrenia is favourable after single 














World Health Organization has repeatedly reiterated that most 
psychiatric disorders in developing countries should be treated in 
primary care in developing countries. This is necessitated not only by 
the very inadequate specialist services but this also helps to reduce 
stigma and institutionalization. This is also consistent with the fact 
which emphasize that “early detection of psychosis, minimizing 
delays in obtaining treatment, monitoring the patient’s condition and 
adherence to treatment, and prompt intervention at times of relapse 
or psychosocial crises”178, 179, 187, 189-192. Keeping this in consideration, 
the knowledge and practices of general practitioners appear to have 
an important role in managing patients with schizophrenia. This is 
even more appropriate when we consider the unavailability of 
community services in our set up193.  
The limitations of this survey should be kept in mind. The 
assessment of knowledge and practice was based on a cross 
sectional view of the GPs responses to a questionnaire. The sample 
in this study may not be representative of the GPs. The results of our 
study may not be generalisable to other settings as the training and 
role of general practitioners may vary in the international healthcare 
system19. However, we had a good response rate and were able to 
contact most of the GPs working in Peshawar District which was 
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even better than a similar study conducted in a small semi urban 
border district of Pakistan22.  
Majority of respondents were male GPs .This perhaps reflects limited 
number of female doctors who are mostly limited to providing 
obstetric services.  
International multicentre survey of general practitioners indicates that 
the mean number of patients with chronic schizophrenia seen by 
general practitioners is similar across several countries and 
healthcare systems194. Although, little is known about general 
practitioners’ experiences in treating schizophrenia, most of them are 
currently treating patients with schizophrenia in a small number (on 
average about 3 patients) which is similar to our finding where only 
13.2% (n=15) treated more than 10 patients annually as compared to 
53.5 % (n=61) general practitioners who didn’t treat any diagnosed 
case of schizophrenia in a year making almost two patients on 
average22, 186, 195.  
It is reported internationally that 40-50% of general practitioners 
screen patients for mental health issues routinely but depression is 
often not identified193. When a much common condition like 
depression can be missed often, schizophrenia has all the chances 
to be missed which was obvious from our findings where 40.4% 
(n=46) didn’t diagnose any new case in a year’s time. 
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In our study, only 6.1% General Practitioners received continuing 
medical education, an essential ingredient to maintain competence, 
regarding schizophrenia which, however, is slightly better than none 
reported in the study by Akhtar et al, but far less than the 30.8% of 
GPs receiving recent medical education about mental health 
problems as reported in another study from Pakistan22, 196. 
Regarding the knowledge, only 12.3% general practitioners in our 
sample had adequate knowledge about schizophrenia which visibly 
speaks about the current state of the affair in Pakistan and is in 
contrast with the findings of a French study where GPs had a fair 
theoretical knowledge of schizophrenia symptoms197.  
As compared to the figures reported by the Swiss and a local study 
(62% and 64% respectively), Hallucinations and delusions were 
considered as the most frequently experienced symptoms of 
schizophrenia by 81.6% of the general practitioners in our sample19, 
22. However, Bizzare behavior which was considered by 56% in 
Swiss study was considered by only 45.2% GPs of our sample19.  
General practitioners in our sample (62.3%) considering that the first 
episode of schizophrenia is preceded by early warning signs were 
much less than the Swiss study (90%) but comparable to another 
local study (69%) 19, 22. This is an alarming situation as it shows the 
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unpreparedness of encountering schizophrenia by general 
practitioners.  
Pharmacotherapy, alone or in possible combination with other types 
of therapy, was considered ideal treatment by 88% of GPs in the 
Swiss sample and 60% in Akhtar et al sample 19, 22. Our results were 
in between the two, where 70.2% GPs considered pharmacotherapy 
to be ideal.  
Only 13.2% and 14% GPs of our sample were able to answer 
correctly the duration of antipsychotic medication to be maintained 
for more than 12 months after first schizophrenic episode, and for at 
least 3 years in patients with multiple episodes of illness after 
remission198. Figures of 12.5% and 39% respectively were reported 
for the same in a similar study 22. This is distressing to know as it 
suggest that even those patients who are diagnosed as cases of 
schizophrenia, may receive incomplete treatment regime leading to 
more chances of relapse. 
Seventy one percent GPs in our sample correctly estimated the 
relapse risk of untreated patients during the first year after a first 
schizophrenic episode which was more than those correctly reported 
by GPs in other studies 19, 22. 
Regarding their practices, the answers given to the questions in the 
questionnaire may not assess their actual practice, but should be 
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considered more of a proxy measure199. Only 20.2% (n=23) of the 
general practitioners had adequate practice in management of 
schizophrenia. This percentage was much less than the percentage 
of any practice question answered by General Practitioners in a 
similar study conducted in Switzerland19. 
In our sample, 76.3% GPs, each, relied on personal history and 
observation over several months for the confirmation of the diagnosis 
of schizophrenia while the GPs in Swiss study showed more reliance 
on Information from significant others (65%) and Family history 
(63%) respectively 19. The sample in the study by Akhtar et al relied 
more on personal history (87.5%) and family history (70%) 
respectively 22. All of these serve as important diagnostic predictors 
of schizophrenia200. 
As compared to a figure of 6.9% referrals of all the patients to 
specialists, 39.5% GPs in our sample showed the same practice 
which though is much bigger than that reported in the Swiss study, 
is far less than the 60% reported in another study 19, 22. However 
61.4% of the general practitioners were of the opinion of 
collaborating with the specialists which is comparable to 77.2% in 
the Swiss survey which is an encouraging finding 19. 
Antipsychotics (one or more) were mentioned as commonly used 
drug for schizophrenia in their practice by 42.1% of GPs which is far 
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less than the figures reported in other studies (80% and 98.5% 
respectively) 19, 22. A study from Pakistan reported that the problem in 
the rational use of psychotropic medication is due to the gaps in GPs' 
knowledge about the management of mental disorders196. This is an 
area of great concern as it poses serious questions not only on the 
practice but on the basic medical knowledge of these GPs. 
The results of the study are not surprising in view of the fact that 
teaching and training in Psychiatry is still much limited in 
undergraduate curriculum in most medical schools in Pakistan. There 
is little or no training in psychiatry for family physicians and 
continuing medical education hardly exists. This may well be 
contributing to a long Duration of Untreated psychosis in the First 
Episode which is found to be more than two years in developing 
countries. 
Although there are studies on evaluation of the training programmes 
for GPs18, 201 but we believe this is a unique study assessing the 
knowledge and practice of doctors working in general practice about 
schizophrenia in a major urban area of a developing country setting. 
It appears that many educational programmes for GPs have been 
devised without assessing the prior knowledge, practice and training 
needs of the GPs. These findings have serious implications for 
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training the general practitioners in diagnosing and treating the 
Schizophrenia. 
As the overall prevalence of schizophrenia is low, it can be argued 
that it will be insufficient to improve knowledge and practices of 
general practitioners only through educational programmes. In 
addition, synchronized provision of specialized services and 
assessment facilities for general practitioners may prove to be 
more important19. From the general practitioners’ point of view, 
communication between the specialist and primary care services 
has been poor and problematic with unclear individual roles and 
responsibilities while treating patients with schizophrenia and this 
may appear to be the biggest hindrance in service provision17, 186. 
An integrated system of care should be developed with clearly 
defined role of GP in the chain of care, which has been a pillar of 
Mental Health Plan for Pakistan202, 203. Such a system would 
significantly contribute to the quality of care provided to the patients 
with Schizophrenia201. 
Since it has already been established that rapid social integration 
can be achieved if the follow up of patients with schizophrenia is 
arranged in general practice, the role of general practitioner for 
dealing with somatic symptoms of the illness and 
renewing/changing their anti psychotic medication can’t be 
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emphasized any more204, 205. This will definitely lead to a much 
needed collaborative care approach204, 206-208. 
The use of universal screening by all general practitioners is needed 
to improve detection rates for which brief mental health screening 
questionnaires might be very useful and consideration should be 
given to the development of standardized methods, suggested by 



















The findings of this study suggest that regarding schizophrenia, the 
knowledge and practices of general practitioners in a major urban 
centre in Pakistan are poor and may be one of the reasons 
responsible for delayed diagnosis and perhaps inadequate 
treatment. The training and education for general practitioners in the 
diagnosis and treatment of schizophrenia needs to be improved 
significantly through more refined, result oriented mental health 
education. At the same time, communication between mental health 
services and general practitioners need particular improvement 
which will not only lead to better access to services but also to 







CHAPTER 3: TABLES AND FIGURES 
 
Table 1: Characteristics of the General Practitioners 
surveyed (n=114) 
 
Characteristics Number (%) 






Number of schizophrenia patients treated annually:   
None                                                                                  
1 – 2 patients 
3 – 5 patients 
6 – 9 patients 







Time taken to treat a patient:             
Less than 10 minutes 
10 – 20 minutes 
21 – 30 minutes 








Number of suspected cases of schizophrenia seen annually: 
None 
1 – 2 patients 
3 – 5 patients 





























Composite Knowledge Scores Number (%) 
No Knowledge = 0 Score 7 (6.1) 
Poor Knowledge = Scores < 12 93 (81.6) 



































Table 3: Correct responses of General Practitioners on 
multi item knowledge questions 
 
 
Multi Item Knowledge Questions Number (%) 
Most frequent symptoms of Schizophrenia             
Hallucinations/delusions
    
 
Social withdrawal





    
 
Suicidality
      
 
Depression/anxiety
     
 
Bizarre behaviour
     
 
Drug misuse




















































Composite Practice Scores Number (%) 
No Practice = 0 Score 10 (8.8) 
Inadequate Practice = Scores < 13 72 (63.1) 



































Table 5: Correct responses of General Practitioners on 








Multi Item Practice Questions Number (%) 
General reliance on confirmation of diagnosis: 
Personal history
      
 
Family history














Observation over several months
    
 
Neurological assessment
     
 
Neuropsychological assessment










      
 
Urine testing for drug abuse
    
 
Consultation with/referral to a specialist














Treatment alone or in collaboration with other specialists or institutions: 
    Treatment exclusively in my clinic 
    Occasional/regular consultation with a specialist to reassess/ advise   
    Referral to a specialist for initial diagnosis and to establish the  
medication regimen, continuation of treatment in my clinic 
    Referral to a specialist/psychiatric out-patient department and complete 



















Prognosis of a treated patient after a first episode of schizophrenia: 
Favourable; Single episode with maintenance
 
of performance level is possible    
Mostly several episodes
 







episodes with progressive decline of performance
 
level and 
             severe
 








Figure 1: Knowledge scores on the frequent 
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Figure 2: The distribution of composite knowledge 
scores of the Practitioners on schizophrenia 
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Figure 3: The distribution of composite practice 
scores of Practitioners on schizophrenia diagnosis, 
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CHAPTER 5: APPENDIX ‘A’ 
KNOWLEDGE AND PRACTICES OF GENERAL PRACTITIONERS 
OF DISTRICT PESHAWAR ABOUT SCHIZOPHRENIA 
 
5.1 PROFORMA 
      
Direction: Kindly fill the proforma and where required put a  in 
the appropriate box 
 
 




 GENERAL INFORMATION 
 
 Name: ______________________________________________ 
 
 Gender:  
 Male         
 Female        
 
 How many patients with an established diagnosis of 
schizophrenia do you treat annually?  
 None          
 1–2          
 3–5          
 6–9          
 More than 10        
 
 How much time do you generally take for a consultation by 
someone with schizophrenia?  
 Less than 10 min        
 10–20 min         
 20–30 min         
 More than 30 min        
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 How many patients in whom you suspect the onset of 
schizophrenia do you see in your practice?  
 None          
 1–2/year         
 3–5/year         




 Which of the following do you think are the most frequent 
symptoms of Schizophrenia? (more than one answer allowed)  
 Hallucinations/delusions       
 Social withdrawal        
 Psychosomatic complaints       
 Suicidality         
 Depression/anxiety        
 Bizarre behaviour        
 Drug misuse         
 Conflicts with parents/teachers/employers    
 Functional decline (school/work)      
 
 Do you think that a first episode of schizophrenia is preceded by 
early warning signs?  
 Yes         
 No          
 
 What therapy in your thinking is ideal for a patient with a 
suspected first schizophrenic episode (independent of whether 
you treat these patients yourself)? (more than one answer 
allowed)  
 Psychotherapy        
 Pharmacotherapy        
 Family therapy        




 For how long should antipsychotic medication be maintained after 
a first schizophrenic episode?  
 Few days         
 3–4 weeks         
 1–6 months         
 6–12 months        
 12–24 months        
 3–5 years         
 
 For how long should antipsychotic medication be maintained in 
patients with multiple episodes of illness after the remission of an 
episode?  
 Few days         
 3–4 weeks         
 1–6 months         
 6–12 months        
 12–24 months        
 At least 3–5 years        
 
 How high do you estimate the relapse risk of untreated patients 




 Which are the two clinically most relevant side-effects of 

















 What do you generally do to confirm the diagnosis? (more than 
one answer allowed)  
 Personal history        
 Family history        
 Information from significant others(teacher/employer)   
 Observation over several days and weeks    
 Observation over several months      
 Neurological assessment       
 Neuropsychological assessment      
 Other examinations(radiographic,electrophysiological)  
 Laboratory tests        
 Urine testing for drug abuse      
 Consultation with/referral to a specialist     
 Other (specify) ________________________________ 
 
 Are these patients treated by you alone, or in collaboration with 
other specialists or institutions? (more than one answer allowed)  
 Treatment exclusively in my clinic     
 Occasional/regular consultation with a specialist to reassess/ 
advise         
 Referral to a specialist for initial diagnosis and to  establish 
the medication regimen, continuation of treatment in my 
clinic         
 Referral to a specialist/psychiatric out-patient department 









 What medications are commonly used in patients with 
schizophrenia and what are the doses? 
  
 
_________________________________(name) _____________________mg/day  
_________________________________(name) _____________________mg/day  
_________________________________(name) _____________________mg/day  
_________________________________(name) _____________________mg/day  
 
 Based on your experience, how do you judge the prognosis of a 
treated patient after a first schizophrenic episode? (more than one 
answer allowed)  
 The prognosis may be favourable; one single episode with 
maintenance of performance level is possible    
 Mostly several episodes with possible maintenance of 
performance level        
 Mostly several episodes with progressive decline of 
performance level and severe course of illness    
 
 Did you participate in continuing education on schizophrenia or 
early schizophrenic psychosis in the past few months?  
 No          











Thank you for your participation 
